Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Hormone Resistance Syndrome | 3 | 2021 | 15 | 1.960 |
Why?
|
Thyroid Neoplasms | 12 | 2024 | 2330 | 1.810 |
Why?
|
Thyroid Hormone Receptors beta | 3 | 2021 | 21 | 1.510 |
Why?
|
Thyroid Nodule | 4 | 2024 | 763 | 1.250 |
Why?
|
Thyrotropin | 6 | 2024 | 833 | 1.200 |
Why?
|
Hypothyroidism | 4 | 2021 | 668 | 1.020 |
Why?
|
Renal Plasma Flow | 1 | 2021 | 27 | 0.770 |
Why?
|
Inheritance Patterns | 2 | 2021 | 341 | 0.760 |
Why?
|
Thyroid Gland | 5 | 2024 | 1169 | 0.750 |
Why?
|
Thyroid Hormones | 5 | 2018 | 402 | 0.710 |
Why?
|
Adrenal Glands | 2 | 2011 | 552 | 0.630 |
Why?
|
Gonadal Steroid Hormones | 2 | 2012 | 702 | 0.590 |
Why?
|
Aldosterone | 7 | 2015 | 869 | 0.560 |
Why?
|
Proto-Oncogene Proteins c-ret | 2 | 2016 | 225 | 0.560 |
Why?
|
Mutation | 10 | 2024 | 30002 | 0.530 |
Why?
|
Carcinoma, Medullary | 2 | 2016 | 115 | 0.530 |
Why?
|
Hyperthyroxinemia, Familial Dysalbuminemic | 1 | 2015 | 1 | 0.520 |
Why?
|
Thyroxine-Binding Proteins | 1 | 2015 | 24 | 0.520 |
Why?
|
Thyrotropin, beta Subunit | 1 | 2015 | 4 | 0.510 |
Why?
|
Postmenopause | 4 | 2014 | 2514 | 0.490 |
Why?
|
Adrenal Gland Neoplasms | 5 | 2015 | 732 | 0.480 |
Why?
|
Adrenocortical Adenoma | 2 | 2012 | 46 | 0.480 |
Why?
|
Euthyroid Sick Syndromes | 2 | 2010 | 14 | 0.440 |
Why?
|
Hyperthyroidism | 2 | 2020 | 294 | 0.440 |
Why?
|
Adrenal Cortex Neoplasms | 2 | 2012 | 161 | 0.430 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2021 | 2455 | 0.410 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2023 | 2054 | 0.400 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2021 | 2058 | 0.400 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2021 | 2864 | 0.390 |
Why?
|
Biopsy, Fine-Needle | 5 | 2024 | 1118 | 0.380 |
Why?
|
Genetic Association Studies | 2 | 2018 | 2731 | 0.360 |
Why?
|
Hyperaldosteronism | 4 | 2015 | 247 | 0.350 |
Why?
|
Sepsis | 1 | 2024 | 2585 | 0.350 |
Why?
|
Prenatal Diagnosis | 1 | 2017 | 1267 | 0.350 |
Why?
|
Hypokalemic Periodic Paralysis | 1 | 2010 | 7 | 0.350 |
Why?
|
Thyroxine | 3 | 2020 | 665 | 0.330 |
Why?
|
Estrogen Receptor alpha | 1 | 2013 | 582 | 0.320 |
Why?
|
Thyroid Function Tests | 3 | 2021 | 288 | 0.310 |
Why?
|
Acromegaly | 1 | 2011 | 310 | 0.310 |
Why?
|
Pituitary Neoplasms | 3 | 2014 | 1322 | 0.300 |
Why?
|
Stroke | 5 | 2013 | 9721 | 0.290 |
Why?
|
Hydrocortisone | 7 | 2015 | 1818 | 0.280 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2021 | 2254 | 0.280 |
Why?
|
Arteries | 1 | 2012 | 1121 | 0.270 |
Why?
|
Pregnancy Outcome | 1 | 2017 | 2923 | 0.270 |
Why?
|
Human Growth Hormone | 1 | 2011 | 642 | 0.270 |
Why?
|
Cerebrovascular Disorders | 1 | 2012 | 1474 | 0.250 |
Why?
|
Triiodothyronine | 4 | 2020 | 492 | 0.240 |
Why?
|
Estradiol | 1 | 2012 | 1937 | 0.240 |
Why?
|
Hypertension | 6 | 2015 | 8536 | 0.230 |
Why?
|
Pregnancy Complications | 1 | 2017 | 2949 | 0.220 |
Why?
|
Enhancer Elements, Genetic | 2 | 2024 | 1360 | 0.220 |
Why?
|
Adrenal Cortex Hormones | 1 | 2012 | 1878 | 0.210 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2024 | 361 | 0.210 |
Why?
|
Microsatellite Repeats | 1 | 2024 | 782 | 0.190 |
Why?
|
Hypertension, Renal | 1 | 2021 | 135 | 0.190 |
Why?
|
Ultrasonography | 3 | 2024 | 5969 | 0.190 |
Why?
|
Propylthiouracil | 1 | 2020 | 68 | 0.180 |
Why?
|
Leukocyte Count | 1 | 2024 | 1597 | 0.180 |
Why?
|
Antithyroid Agents | 1 | 2020 | 72 | 0.180 |
Why?
|
Mental Retardation, X-Linked | 1 | 2020 | 41 | 0.180 |
Why?
|
Humans | 52 | 2024 | 761208 | 0.170 |
Why?
|
Watchful Waiting | 1 | 2024 | 489 | 0.170 |
Why?
|
Iodide Peroxidase | 1 | 2021 | 294 | 0.170 |
Why?
|
Diet, Sodium-Restricted | 1 | 2021 | 291 | 0.170 |
Why?
|
Fetal Therapies | 1 | 2020 | 101 | 0.170 |
Why?
|
Muscle Hypotonia | 1 | 2020 | 161 | 0.160 |
Why?
|
Chromogranins | 1 | 2020 | 160 | 0.160 |
Why?
|
Heterozygote | 2 | 2016 | 2778 | 0.160 |
Why?
|
Female | 35 | 2024 | 392544 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 17897 | 0.150 |
Why?
|
Prognosis | 6 | 2023 | 29687 | 0.150 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 195 | 0.150 |
Why?
|
Carcinoma, Papillary | 1 | 2023 | 785 | 0.150 |
Why?
|
Hemodynamics | 2 | 2021 | 4165 | 0.150 |
Why?
|
Severity of Illness Index | 6 | 2013 | 15841 | 0.150 |
Why?
|
Muscular Atrophy | 1 | 2020 | 334 | 0.140 |
Why?
|
Male | 28 | 2024 | 360693 | 0.140 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2021 | 695 | 0.140 |
Why?
|
Middle Aged | 26 | 2024 | 220853 | 0.140 |
Why?
|
Adult | 21 | 2024 | 221119 | 0.130 |
Why?
|
Thyroxine-Binding Globulin | 1 | 2015 | 1 | 0.120 |
Why?
|
Diazoxide | 1 | 2015 | 52 | 0.120 |
Why?
|
Pedigree | 3 | 2024 | 4537 | 0.120 |
Why?
|
Aged | 18 | 2024 | 169288 | 0.120 |
Why?
|
Pakistan | 1 | 2015 | 292 | 0.120 |
Why?
|
Ergolines | 1 | 2014 | 57 | 0.120 |
Why?
|
Calcitonin | 1 | 2015 | 329 | 0.110 |
Why?
|
Optic Chiasm | 1 | 2014 | 91 | 0.110 |
Why?
|
Obesity | 2 | 2013 | 12939 | 0.110 |
Why?
|
DNA-Cytosine Methylases | 1 | 2013 | 17 | 0.110 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2013 | 4014 | 0.110 |
Why?
|
Prolactinoma | 1 | 2014 | 113 | 0.110 |
Why?
|
Consanguinity | 1 | 2015 | 457 | 0.110 |
Why?
|
Amino Acid Substitution | 1 | 2017 | 1737 | 0.110 |
Why?
|
Encephalocele | 1 | 2014 | 135 | 0.100 |
Why?
|
Retrospective Studies | 8 | 2024 | 80674 | 0.100 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2013 | 765 | 0.100 |
Why?
|
Hyperinsulinism | 1 | 2015 | 400 | 0.100 |
Why?
|
Glycine | 1 | 2015 | 659 | 0.100 |
Why?
|
Prospective Studies | 5 | 2022 | 54435 | 0.100 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2014 | 163 | 0.100 |
Why?
|
Carcinoma | 1 | 2023 | 2330 | 0.100 |
Why?
|
Arginine | 1 | 2015 | 920 | 0.090 |
Why?
|
Adrenal Cortex | 1 | 2012 | 134 | 0.090 |
Why?
|
Androstenedione | 1 | 2011 | 131 | 0.090 |
Why?
|
Dopamine Agonists | 1 | 2014 | 352 | 0.090 |
Why?
|
Genotype | 2 | 2017 | 12985 | 0.090 |
Why?
|
Radioimmunoassay | 1 | 2011 | 862 | 0.090 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 2011 | 241 | 0.090 |
Why?
|
Homozygote | 1 | 2015 | 1775 | 0.090 |
Why?
|
Incidental Findings | 2 | 2012 | 698 | 0.090 |
Why?
|
Pituitary Diseases | 1 | 2011 | 135 | 0.090 |
Why?
|
Insulinoma | 1 | 2010 | 121 | 0.080 |
Why?
|
Azathioprine | 1 | 2011 | 354 | 0.080 |
Why?
|
Case-Control Studies | 7 | 2020 | 22174 | 0.080 |
Why?
|
Birth Weight | 1 | 2017 | 2104 | 0.080 |
Why?
|
Aged, 80 and over | 7 | 2024 | 58952 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2012 | 549 | 0.080 |
Why?
|
Adrenalectomy | 1 | 2010 | 346 | 0.080 |
Why?
|
Glucose Tolerance Test | 1 | 2011 | 1178 | 0.080 |
Why?
|
Mutation, Missense | 1 | 2017 | 2567 | 0.080 |
Why?
|
MicroRNAs | 1 | 2024 | 3758 | 0.080 |
Why?
|
Hypoglycemia | 1 | 2015 | 883 | 0.070 |
Why?
|
Protein Conformation | 1 | 2015 | 3933 | 0.070 |
Why?
|
Mothers | 1 | 2017 | 2193 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9187 | 0.070 |
Why?
|
Signal Transduction | 2 | 2021 | 23416 | 0.070 |
Why?
|
Cardiovascular Diseases | 1 | 2012 | 15520 | 0.070 |
Why?
|
Gene Frequency | 1 | 2013 | 3603 | 0.070 |
Why?
|
Fatty Liver | 1 | 2012 | 789 | 0.070 |
Why?
|
Genetic Testing | 2 | 2016 | 3537 | 0.060 |
Why?
|
Adenocarcinoma | 1 | 2023 | 6341 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2011 | 2928 | 0.060 |
Why?
|
Cohort Studies | 3 | 2021 | 41496 | 0.060 |
Why?
|
Osteoporosis | 1 | 2015 | 1604 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2022 | 4872 | 0.060 |
Why?
|
Follow-Up Studies | 4 | 2024 | 39126 | 0.060 |
Why?
|
Models, Molecular | 1 | 2015 | 5406 | 0.060 |
Why?
|
Young Adult | 8 | 2021 | 59221 | 0.060 |
Why?
|
Digestive System Surgical Procedures | 1 | 2010 | 571 | 0.060 |
Why?
|
Body Mass Index | 4 | 2022 | 12952 | 0.060 |
Why?
|
Prevalence | 4 | 2015 | 15721 | 0.060 |
Why?
|
Antihypertensive Agents | 1 | 2014 | 2019 | 0.060 |
Why?
|
Vitamin D | 2 | 2015 | 3301 | 0.060 |
Why?
|
Sequence Analysis, DNA | 1 | 2015 | 4739 | 0.060 |
Why?
|
Alleles | 1 | 2015 | 6857 | 0.060 |
Why?
|
Neoplasms | 4 | 2013 | 22140 | 0.050 |
Why?
|
Adrenocorticotropic Hormone | 2 | 2015 | 617 | 0.050 |
Why?
|
Odds Ratio | 2 | 2013 | 9652 | 0.050 |
Why?
|
Renin | 2 | 2015 | 639 | 0.050 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 1405 | 0.050 |
Why?
|
Pain Measurement | 1 | 2012 | 3549 | 0.050 |
Why?
|
Overweight | 1 | 2013 | 2418 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 26071 | 0.050 |
Why?
|
Calcium | 1 | 2015 | 5719 | 0.050 |
Why?
|
Laparoscopy | 2 | 2010 | 2035 | 0.050 |
Why?
|
Recovery of Function | 1 | 2012 | 2981 | 0.050 |
Why?
|
Primates | 1 | 2024 | 521 | 0.050 |
Why?
|
Sex Characteristics | 1 | 2012 | 2640 | 0.050 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2015 | 339 | 0.050 |
Why?
|
Platinum | 1 | 2022 | 220 | 0.050 |
Why?
|
Adolescent | 6 | 2021 | 88298 | 0.050 |
Why?
|
Blood Pressure | 2 | 2014 | 8479 | 0.050 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2020 | 80 | 0.040 |
Why?
|
Stress, Psychological | 1 | 2015 | 4487 | 0.040 |
Why?
|
Pregnancy | 2 | 2020 | 29893 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 793 | 0.040 |
Why?
|
Liver | 1 | 2015 | 7514 | 0.040 |
Why?
|
Risk Factors | 4 | 2014 | 74239 | 0.040 |
Why?
|
Amniotic Fluid | 1 | 2020 | 378 | 0.040 |
Why?
|
Atherosclerosis | 1 | 2014 | 3406 | 0.040 |
Why?
|
Immunosuppressive Agents | 1 | 2011 | 4190 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2011 | 12052 | 0.040 |
Why?
|
Symporters | 1 | 2020 | 363 | 0.040 |
Why?
|
Critical Illness | 1 | 2010 | 2724 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2010 | 3744 | 0.030 |
Why?
|
Child, Preschool | 2 | 2020 | 42224 | 0.030 |
Why?
|
Logistic Models | 1 | 2011 | 13249 | 0.030 |
Why?
|
Europe | 2 | 2013 | 3423 | 0.030 |
Why?
|
Diagnostic Imaging | 1 | 2010 | 3534 | 0.030 |
Why?
|
Mutant Chimeric Proteins | 1 | 2015 | 20 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 15920 | 0.030 |
Why?
|
Steroid 11-beta-Hydroxylase | 1 | 2015 | 20 | 0.030 |
Why?
|
G Protein-Coupled Inwardly-Rectifying Potassium Channels | 1 | 2015 | 61 | 0.030 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 1 | 2015 | 40 | 0.030 |
Why?
|
Treatment Outcome | 5 | 2015 | 64681 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2010 | 12976 | 0.030 |
Why?
|
Greece | 1 | 2015 | 340 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2012 | 20588 | 0.030 |
Why?
|
Fludrocortisone | 1 | 2013 | 24 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2024 | 5250 | 0.030 |
Why?
|
Education, Nursing | 1 | 2013 | 80 | 0.030 |
Why?
|
Diagnostic Techniques, Endocrine | 1 | 2013 | 43 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2022 | 1212 | 0.030 |
Why?
|
Sex Ratio | 1 | 2013 | 107 | 0.030 |
Why?
|
Nursing Assessment | 1 | 2012 | 106 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2010 | 5366 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 2015 | 1030 | 0.020 |
Why?
|
Hospitalization | 1 | 2011 | 10707 | 0.020 |
Why?
|
Thyroid Diseases | 1 | 2015 | 386 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2012 | 518 | 0.020 |
Why?
|
Asymptomatic Diseases | 1 | 2014 | 588 | 0.020 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2015 | 624 | 0.020 |
Why?
|
Regression Analysis | 2 | 2012 | 6345 | 0.020 |
Why?
|
Thyroidectomy | 1 | 2015 | 908 | 0.020 |
Why?
|
Self Efficacy | 1 | 2013 | 636 | 0.020 |
Why?
|
Seasons | 1 | 2015 | 1518 | 0.020 |
Why?
|
Tomography, Spiral Computed | 1 | 2010 | 273 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2011 | 13632 | 0.020 |
Why?
|
Haplotypes | 1 | 2015 | 2715 | 0.020 |
Why?
|
Tumor Burden | 1 | 2014 | 1892 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2012 | 1838 | 0.020 |
Why?
|
Anthropometry | 1 | 2012 | 1338 | 0.020 |
Why?
|
Parathyroid Hormone | 1 | 2014 | 1803 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 4 | 2020 | 36415 | 0.020 |
Why?
|
Visual Fields | 1 | 2014 | 1059 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2217 | 0.020 |
Why?
|
Vision Disorders | 1 | 2014 | 1088 | 0.020 |
Why?
|
Animals | 2 | 2024 | 168079 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 4107 | 0.020 |
Why?
|
Endosonography | 1 | 2010 | 608 | 0.020 |
Why?
|
Causality | 1 | 2012 | 1244 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9278 | 0.020 |
Why?
|
Pancreatectomy | 1 | 2010 | 811 | 0.020 |
Why?
|
Dexamethasone | 1 | 2013 | 1945 | 0.020 |
Why?
|
Adenoma | 1 | 2015 | 2159 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2012 | 2420 | 0.010 |
Why?
|
Cross Infection | 1 | 2012 | 1422 | 0.010 |
Why?
|
Time Factors | 2 | 2015 | 39957 | 0.010 |
Why?
|
Predictive Value of Tests | 2 | 2010 | 15308 | 0.010 |
Why?
|
History, 20th Century | 1 | 2010 | 2765 | 0.010 |
Why?
|
Population Surveillance | 1 | 2012 | 2598 | 0.010 |
Why?
|
Seizures | 1 | 2014 | 2965 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 24021 | 0.010 |
Why?
|
Acute Disease | 1 | 2010 | 7226 | 0.010 |
Why?
|
Body Weight | 1 | 2010 | 4618 | 0.010 |
Why?
|
Patient Selection | 1 | 2010 | 4246 | 0.010 |
Why?
|
Clinical Competence | 1 | 2013 | 4788 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10516 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2011 | 3952 | 0.010 |
Why?
|
Child | 2 | 2015 | 80152 | 0.010 |
Why?
|
Survival Rate | 1 | 2010 | 12728 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13511 | 0.010 |
Why?
|
Survival Analysis | 1 | 2007 | 10088 | 0.010 |
Why?
|
Brain | 1 | 2020 | 27092 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 20119 | 0.010 |
Why?
|
Quality of Life | 1 | 2011 | 13367 | 0.010 |
Why?
|